Esprit BTK Everolimus Eluting Resorbable Scaffold System

The Esprit BTK Everolimus Eluting Resorbable Scaffold System is a first-in-class, FDA-approved drug-eluting resorbable scaffold designed for the treatment of chronic limb-threatening ischemia (CLTI) in patients with below-the-knee (BTK) peripheral arterial disease. The device consists of an absorbable mesh tube that is coated with everolimus and implanted into narrowed arteries in the lower leg to restore blood flow and prevent vessel re-narrowing. Unlike permanent metal stents, the scaffold provides temporary mechanical support while gradually releasing everolimus to inhibit neointimal hyperplasia and then fully resorbs over time. The mechanism of action involves local delivery of everolimus, which inhibits growth factor-stimulated cell proliferation by forming a complex with FKBP-12 and interfering with mTOR signaling, leading to cell cycle arrest at late G1 phase. Clinical trials have demonstrated superior efficacy compared to balloon angioplasty alone in maintaining vessel patency and reducing major adverse limb events[2][3][4][5][6][8].

Brand names

Esprit BTK

Other names

Esprit BTK Resorbable Scaffold SystemEsprit BTK Everolimus Eluting Resorbable Scaffold SystemEsprit™ BTK